CLINICAL_TRIALS ClinicalTrials.gov record update

An Open-label, Dose Escalation Phase 1 Study to Investigate HLX06, a Humanized Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2, in Patients With Advanced Solid Tumors Refractory to Standard Therapy

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03494231
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:12.965999+00:00
Published At: 2019-07-30T00:00:00+00:00
Record Updated At: 2019-07-30
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Solid Tumor, Adult"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2019-07-30"
protocolSection.identificationModule.nctId: "NCT03494231"
protocolSection.identificationModule.officialTitle: "An Open-label, Dose Escalation Phase 1 Study to Investigate HLX06, a Humanized Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2, in Patients With Advanced Solid Tumors Refractory to Standard Therapy"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.